Serena claims ‘discrimination’ over drug tests
She said she had been tested five times in June, compared to one or none from some of her compatriots.
US player Serena Williams reacts after losing a point against against Germany’s Angelique Kerber during their women’s singles final match on the twelfth day of the 2018 Wimbledon Championships at The All England Lawn Tennis Club in Wimbledon, southwest London, on July 14, 2018. Kerber won the match 6-3, 6-3. / AFP PHOTO / Oli SCARFF / RESTRICTED TO EDITORIAL USE
Serena Williams claims she is the victim of “discrimination” by US doping chiefs who are testing her more than other players.
At Wimbledon Williams slammed “shocking” treatment over excessive targeting from testers in the run-up to the second Grand Slam of the season.
And in a tweet on Wednesday the 23-time Grand slam winner reignited the discussion.
“…..and it’s that time of the day to get “randomly” drug tested and only test Serena,” she posted on her official Twitter page.
“Out of all the players it’s been proven I’m the one getting tested the most. Discrimination? I think so. At least I’ll be keeping the sport clean #StayPositive,” she wrote.
The 36-year-old battled back from life-saving surgery after giving birth to get within touching distance of an eighth Wimbledon title.
However, the American suffered a straight sets defeat by Angelique Kerber in the women’s final on July 14.
She had arrived at the tournament on the back of a report revealing her anger about an unannounced test in June where the tester refused to leave her Florida house.
Williams said at the time she had been tested five times on June, compared to one or none from some of her compatriots.
Athletes returning from a long absence are often the subject of repeated drug tests, as they are seen as part of a higher-risk category than athletes in the flow of regular competition.
For more sport your way, download The Citizen’s app for iOS and Android.
For more news your way
Download our app and read this and other great stories on the move. Available for Android and iOS.